
Description: "Gardasil: star cancer vaccine" is a comprehensive drug report on the market leader of HPV vaccine segment (according to 2015 sales).

In this report, Gardasil and Gardasil 9 are considered as a single product as Merck & Company reports the sales of both the vaccines collectively. Gardasil is the largest oncology vaccine and the largest in Merck's oncology product portfolio. It is classified under the vaccine therapy and belongs to the HPV vaccine class. It is indicated for the prevention of cervical, vulvar, vaginal, and anal cancers.

It is also approved for non-oncology indications and is known as 'Silgard' in Europe.

The report gives basic information about the vaccine, covering all details from brand name, date of approvals, mechanism of action, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the vaccine, news about Gardasil, information on competitor vaccine, number of clinical trials (by year and by phase), and so on.

The report gives an analysis of the historical annual sales (from 2006 to Q3-2016), historical quarterly sales (Q1-2012 to Q3-2016) and sales expectations (from 2016 to 2021). The analysis broadly indicates that the vaccine has stronger position in its therapy against its competitor.

Details of the sales analysis section

Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2006 to Q3-2016. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.

Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past 19 quarters from Q1-2012 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for Gardasil sales over 2016-2021. We have highlighted the key reasons for our expectations. All the historical as well as expected sales analysis is based on:

- Total global sales
- US sales
- International sales (Merck sales)

Other important details

Key event tracker: The report highlights key events that have taken place for Gardasil from 2006 to 2016 (along with those events expected in 2016). It gives additional information about the key events that have driven sales for the vaccine over this period.

Clinical trial numbers: The report provides numbers of clinical trials which have started for Gardasil in 2014, 2015 and 2016 and for different phases: phase II, phase II/III and phase III. It gives insights into whether the company is still spending money for taking the vaccine even further for other indications.

Competitive vaccines: Additionally, the vaccine which compete with Gardasil for the prevention of HPV disease listed with the details including brand name, API, company involved and first approval dates. It also provides comparison between the currently prevailing HPV vaccines.

Clinical studies: Efficacy results of Gardasil and other HPV vaccines have been provided.

News: We have listed news related to Gardasil that would impact the vaccine's performance.
Contents:
1. Basic Information
   1.1 Brand name/multiple brand names (US, Europe, Japan, RoW)
   1.2 Research code
   1.3 API
   1.4 Immuno-oncology status
   1.5 Broader indications
   1.6 Therapy class
   1.7 Class of vaccine
   1.8 Companies involved in marketing (US, Europe, Japan, RoW)
   1.9 Innovation-related information
   1.10 First approval dates (US, Europe, Japan)
   1.11 Patent expiry date (US)
   1.12 Molecule type
   1.13 Dosage form/strength
   1.14 Route of administration
   1.15 Global sales-2015/2016E (USD, mn)
   1.16 Mechanism of action
   1.17 Warning and precautions
   1.18 Adverse reactions
   1.19 Royalty-related information
   1.20 Joint venture-related information
   1.21 About the vaccines

2. Approval timeline infographic (2006-2016)

3. Regulatory approval details (US, Europe, Japan and RoW)
   3.1 Approval table (USFDA, EMA and PMDA)
   3.2 Drug approvals in RoW countries

4. Historical annual sales analysis
   4.1 Total annual sales (USD)
   4.2 Total annual oncology sales (USD)
   4.3 Sales mix - US and International
   4.4 US annual sales (USD)
   4.5 US annual oncology sales (USD)
   4.6 International annual sales (USD)
   4.7 International annual oncology sales (USD)
   4.8 JV (SPMSD) annual sales (USD)
   4.9 JV (SPMSD) annual oncology sales (USD)
   4.10 Historical annual sales table (USD)
   4.11 Historical annual oncology sales table (USD)

5. Historical quarterly sales analysis (Q1-2012 – Q3-2016)
   5.1 Total quarterly sales (USD)
   5.2 Total quarterly oncology sales (USD)
   5.3 Sales mix - US and International
   5.4 US quarterly sales (USD)
   5.5 US quarterly oncology sales (USD)
   5.6 International quarterly sales (USD)
   5.7 International quarterly oncology sales (USD)
   5.8 JV (SPMSD) quarterly sales (USD)
   5.9 JV (SPMSD) quarterly oncology sales (USD)
   5.10 Historical quarterly sales table (USD)
   5.11 Historical quarterly oncology sales table (USD)

6. Historical cumulative sales (2006 to Q3-2016)
   6.1 Total cumulative sales (USD)
   6.2 Total cumulative oncology sales (USD)
   6.3 US cumulative sales (USD)
   6.4 US cumulative oncology sales (USD)
   6.5 International cumulative sales (USD)
   6.6 International cumulative oncology sales (USD)
   6.7 Historical cumulative sales table (USD)
6.8 Historical cumulative oncology sales table (USD)

7. Q3-2016 update
7.1 Q3-2015 to Q3-2016 quarterly total sales (USD)
7.2 Q3-2015 to Q3-2016 quarterly total oncology sales (USD)
7.3 Q3-3015 to Q3-3016 quarterly US sales (USD)
7.4 Q3-4015 to Q3-4016 quarterly US oncology sales (USD)
7.5 Q3-2015 to Q3-2016 quarterly international sales (USD)
7.6 Q3-2015 to Q3-2016 quarterly international oncology sales (USD)
7.7 Q3-2015 to Q3-2016 quarterly sales table (USD)
7.8 Q3-2015 to Q3-2016 quarterly sales oncology table (USD)

8. Sales expectations (2016E-2021E)
8.1 Total sales (USD)
8.2 Total oncology sales (USD)
8.3 Sales mix - US and International
8.4 US sales (USD)
8.5 US oncology sales (USD)
8.6 International sales (USD)
8.7 International oncology sales (USD)
8.8 JV (SPMSD) sales (USD)
8.9 JV (SPMSD) oncology sales (USD)
8.10 Historical sales table (USD)
8.11 Historical oncology sales table (USD)

9. List of approved vaccines for HPV-related disease
9.1 HPV vaccines at a glance

10. Clinical studies results of HPV vaccines
10.1 Gardasil
10.2 Gardasil 9
10.3 Cervarix

11. Event tracker

12. Clinical trials of Gardasil (US)
12.1 Year-wise (2014, 2015 and 2016)
12.2 Phase-wise (II, II/III, III)

13. News around Gardasil (including 11 press releases)

14. Methodology

15. Annexure
15.1 Drug coverage list of 251 drugs
15.3 Disclaimer

List of Exhibits

Exhibit 1: Approval infographic
Exhibit 2: Drug approvals across the three major geographies
Exhibit 3: Drug approvals in RoW countries
Exhibit 4: Historical annual total sales in USD mn
Exhibit 5: Historical annual total oncology sales in USD mn
Exhibit 6: Historical annual sales mix - US and International
Exhibit 7: Historical annual US sales in USD mn
Exhibit 8: Historical annual US oncology sales in USD mn
Exhibit 9: Historical annual International (Merck) sales in USD mn
Exhibit 10: Historical annual International (Merck) oncology sales in USD mn
Exhibit 11: Historical annual JV (SPMSD) sales in USD mn
Exhibit 12: Historical annual JV (SPMSD) oncology sales in USD mn
Exhibit 13: Historical annual sales table in USD mn
Exhibit 14: Historical annual oncology sales table in USD mn
Exhibit 15: Quarterly total sales in USD mn
Exhibit 16: Quarterly total oncology sales in USD mn
Exhibit 17: Quarterly sales mix - US and International
Exhibit 18: Quarterly US sales in USD mn
Exhibit 19: Quarterly US oncology sales in USD mn
Exhibit 20: Quarterly International (Merck) sales in USD mn
Exhibit 21: Quarterly International (Merck) oncology sales in USD mn
Exhibit 22: Quarterly JV (SPMSD) sales in USD mn
Exhibit 23: Quarterly JV (SPMSD) oncology sales in USD mn
Exhibit 24: Quarterly sales table in USD mn
Exhibit 25: Quarterly oncology sales table in USD mn
Exhibit 26: Historical cumulative total sales in USD mn
Exhibit 27: Historical cumulative total oncology sales in USD mn
Exhibit 28: Historical cumulative US sales in USD mn
Exhibit 29: Historical cumulative US oncology sales in USD mn
Exhibit 30: Historical cumulative International (Merck) sales in USD mn
Exhibit 31: Historical cumulative International (Merck) oncology sales in USD mn
Exhibit 32: Historical cumulative sales table in USD mn
Exhibit 33: Historical cumulative oncology sales table in USD mn
Exhibit 34: Q3-2015 to Q3-2016 total sales in USD mn
Exhibit 35: Q3-2015 to Q3-2016 total oncology sales in USD mn
Exhibit 36: Q3-2015 to Q3-2016 US sales in USD mn
Exhibit 37: Q3-2015 to Q3-2016 US oncology sales in USD mn
Exhibit 38: Q3-2015 to Q3-2016 International (Merck) sales in USD mn
Exhibit 39: Q3-2015 to Q3-2016 International (Merck) oncology sales in USD mn
Exhibit 40: Q3-2015 to Q3-2016 sales table in USD mn
Exhibit 41: Q3-2015 to Q3-2016 oncology sales table in USD mn
Exhibit 42: Expected annual total sales in USD mn
Exhibit 43: Expected annual total oncology sales in USD mn
Exhibit 44: Expected annual sales mix - US and International
Exhibit 45: Expected annual US sales in USD mn
Exhibit 46: Expected annual US oncology sales in USD mn
Exhibit 47: Expected annual International (Merck) sales in USD mn
Exhibit 48: Expected annual International (Merck) oncology sales in USD mn
Exhibit 49: Expected annual JV (SPMSD) sales in USD mn
Exhibit 50: Expected annual JV (SPMSD) oncology sales in USD mn
Exhibit 51: Expected annual sales table in USD mn
Exhibit 52: Expected annual oncology sales table in USD mn
Exhibit 53: List of the key vaccines for the prevention of HPV-related disease
Exhibit 54: HPV vaccines at a glance
Exhibit 55: Analysis of efficacy of Gardasil (Study-1)
Exhibit 56: Analysis of efficacy of Gardasil (Study-2)
Exhibit 57: Analysis of efficacy of Gardasil (Study-3)
Exhibit 58: Analysis of efficacy of Gardasil (Study-4)
Exhibit 59: Analysis of efficacy of Gardasil (Study-5)
Exhibit 60: Analysis of efficacy of Gardasil 9 (Study-1)
Exhibit 61: Analysis of efficacy of Gardasil 9 (Study-2)
Exhibit 62: Analysis of efficacy of Gardasil 9 (Study-3)
Exhibit 63: Analysis of efficacy of Cervarix (Study-1)
Exhibit 64: Analysis of efficacy of Cervarix (Study-2)
Exhibit 65: Event tracker mapping the major event related to Gardasil
Exhibit 68: Year-wise clinical trials in US (2014)
Exhibit 69: Table for year-wise clinical trials in US (2016)
Exhibit 70: Table for year-wise clinical trials in US (2015)
Exhibit 71: Table for year-wise clinical trials in US (2014)
Exhibit 72: Phase-wise clinical trials in US (Phase-III)
Exhibit 73: Phase-wise clinical trials in US (Phase-II/III)
Exhibit 74: Phase-wise clinical trials in US (Phase-II)
Exhibit 75: Table for phase-wise clinical trials in US (Phase-III)
Exhibit 76: Table for phase-wise clinical trials in US (Phase-II/III)
Exhibit 77: Table for phase-wise clinical trials in US (Phase-II)
Exhibit 78: Key events summary-covering news related to Gardasil

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/4020281/](http://www.researchandmarkets.com/reports/4020281/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit 
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/4020281/">http://www.researchandmarkets.com/reports/4020281/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC2GBNNH</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 300</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 400</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World